Download presentation
Presentation is loading. Please wait.
Published byΘεόκριτος Δασκαλοπούλου Modified over 6 years ago
1
Reversal Strategies for VKA: Truths and Misconceptions
3
Program Objectives
4
Typical Indications for Anticoagulation Therapy
5
The Coagulation Cascade: Pathways and Factors
6
Coagulation Cascade and Activity Sites of Anticoagulant Therapeutics
7
Warfarin MoA[a,b]
8
Pharmacologic Properties of Selected Oral Anticoagulants
9
Reasons for Urgent Anticoagulation Reversal
10
Reversal Agents for VKA-Associated Anticoagulation
11
VKA Therapy Reversal With Vitamin K
12
FFP for Anticoagulation Reversal
13
Management of Urgent Anticoagulation Reversal
14
Volume Overload and Anticoagulation Reversal With FFP
15
RE-LY Study: Risk of Major Bleeding (% of Patients)
16
Efficacy and Safety of a 4F-PCC in Patients on VKAs Presenting With Major Bleeding: Key Results From a Phase 3b Study
17
Outcomes of Urgent Warfarin Reversal With FFP vs 4F-PCC
18
4F-PCC vs Plasma for Rapid VKA Reversal in Patients Needing Urgent Surgical or Invasive Interventions: Primary Endpoint Results
19
4F-PCC vs Plasma for Rapid VKA Reversal in Patients Needing Urgent Surgical or Invasive Interventions: Adverse Events
20
Increased Risk of Volume Overload With Plasma Compared With 4F-PCC
21
Thromboembolic Events Over Time: Plasma vs 4F-PCC
22
Recombinant FVIIa vs 3F-PCC
23
Warfarin Reversal by 4F-PCC
24
Relative Efficacy of Strategies for Reversal of Oral Anticoagulation
25
Therapeutic Interventions for Reversal of Oral Anticoagulants Based on Urgency[a-e]
26
What Do Guidelines Recommend?
27
Updated European Heart Rhythm Association Practical Guide: Management of NOAC-Associated Bleeding
28
Conclusions
29
Abbreviations
30
Abbreviations (cont)
Similar presentations
© 2024 SlidePlayer.com Inc.
All rights reserved.